T2 Biosystems, Inc. (NASDAQ:TTOO) Short Interest Update

T2 Biosystems, Inc. (NASDAQ:TTOO) saw a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 942,500 shares, an increase of 50.8% from the December 15th total of 624,900 shares. Based on an average daily volume of 900,900 shares, the days-to-cover ratio is currently 1.0 days. Currently, 10.1% of the shares of the stock are sold short.

Analyst Ratings Changes

Separately, StockNews.com assumed coverage on shares of T2 Biosystems in a research report on Monday. They issued a “sell” rating for the company.

Institutional Investors Weigh In On T2 Biosystems

A hedge fund recently bought a new stake in T2 Biosystems stock. Armistice Capital LLC acquired a new stake in T2 Biosystems, Inc. (NASDAQ:TTOO) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 1,658,000 shares of the medical equipment provider’s stock, valued at approximately $8,854,000. Armistice Capital LLC owned 9.49% of T2 Biosystems as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 23.18% of the company’s stock.

T2 Biosystems Trading Down 4.6 %

NASDAQ TTOO traded down $0.01 during trading hours on Thursday, reaching $0.27. The company had a trading volume of 576,931 shares, compared to its average volume of 832,152. T2 Biosystems has a 1-year low of $0.25 and a 1-year high of $6.95. The stock has a 50-day moving average of $0.45 and a 200 day moving average of $2.18.

About T2 Biosystems

T2 Biosystems, Inc, an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine.